Incyte stock after-hours at EUR 100.70: minus 1.71 percent
Published on 10/05/2026 at 23:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Incyte stock was at EUR 100.70 after-hours at 11:00 p.m. CEST on October 5, 2026, down 1.71 percent versus the prior close of EUR 102.45 at Lang & Schwarz. The quoted bid was EUR 100.50 and the ask was EUR 100.90.
Trading day in focus
The Lang & Schwarz price stood EUR 1.75 below the prior close. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Incyte stock.
FDA approval for Atebrioz
In a September 25, 2026 release, Incyte and Mirum Pharmaceuticals said the U.S. Food and Drug Administration approved Atebrioz, or zilurgisertib, for adults and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva. The treatment is designed to reduce the volume of total new heterotopic ossification. The release said Atebrioz was developed by Incyte and licensed to Mirum for worldwide development and commercialization. Incyte also received a Rare Pediatric Disease Priority Review Voucher.
Inflammation and autoimmunity portfolio
In a September 22, 2026 release, Incyte said data from its inflammation and autoimmunity portfolio would be presented at the European Academy of Dermatology and Venereology Congress in Vienna from September 30 through October 3, 2026. The release listed presentations involving ruxolitinib cream and povorcitinib across atopic dermatitis, hidradenitis suppurativa, prurigo nodularis and vitiligo.
